Veeva Systems seems to be a long-term winner in life sciences, in accordance to JPMorgan. Analyst Alexei Gogolev upgraded the cloud options supplier to chubby from impartial and lifted his worth goal by $40 to $330. That implies about 20.9% potential upside for Veeva, which works with prospects throughout the life sciences trade to retailer knowledge and keep regulatory compliance. Shares of Veeva have gained greater than 29% this 12 months. JPMorgan’s improve comes after Veeva in late August reported a second-quarter income and earnings beat, which led to worth goal upgrades from analysts from corporations similar to UBS and Piper Sandler. Gogolev is bullish on Veeva market share alternative within the rising life sciences trade. He estimated the corporate’s whole addressable market to be roughly $20 billion, and famous that Veeva has seen sturdy income development of 20% over the previous 5 years, outpacing the life sciences trade development of mid-single digits. VEEV 1Y mountain Veeva Systems stock efficiency over the previous 12 months. “We see VEEV growing revenue at a ~13% 3-year CAGR and FCF margins of 40%+, supported by competitively differentiated platform-approach and TAM penetration opportunity,” Gogolev wrote in a notice to purchasers. The analyst highlighted the corporate’s not too long ago introduced long-term partnership with medical analysis companies supplier Iqvia as a driver for brand spanking new monetization alternatives and an acceleration in income development. Iqvia, which had a number of authorized disputes with Veeva, joined forces final month to enable their knowledge to be used with one another’s software program or companies for patrons. “Despite strong competition from Salesforce, we are raising VEEV rating to OW relative to our vertical SaaS coverage as we are encouraged by the opportunities unlocked by the recent IQVIA partnership and Agentic AI implementation. Given a healthy rule of 50 combination, we believe the stock deserves to re-rate from current 24x CY26E EV/EBITDA,” he mentioned, including that “no player in the space has the same level of depth and breadth of product offering” as Veeva. Shares rose greater than 1% within the premarket following the improve. Most analysts are bullish on Veeva, with 19 of 32 ranking it a purchase or sturdy purchase, LSEG knowledge exhibits.